[go: up one dir, main page]

BR9408478A - Compound pharmaceutical composition processes of treatment of a disease susceptible to treatment with non-steroidal anti-inflammatory agent and treatment of diseases measured by cyclooxygenase, pharmaceutically effective salt and use of a compound - Google Patents

Compound pharmaceutical composition processes of treatment of a disease susceptible to treatment with non-steroidal anti-inflammatory agent and treatment of diseases measured by cyclooxygenase, pharmaceutically effective salt and use of a compound

Info

Publication number
BR9408478A
BR9408478A BR9408478A BR9408478A BR9408478A BR 9408478 A BR9408478 A BR 9408478A BR 9408478 A BR9408478 A BR 9408478A BR 9408478 A BR9408478 A BR 9408478A BR 9408478 A BR9408478 A BR 9408478A
Authority
BR
Brazil
Prior art keywords
treatment
compound
cyclooxygenase
pharmaceutical composition
steroidal anti
Prior art date
Application number
BR9408478A
Other languages
Portuguese (pt)
Inventor
Yves Ducharme
Jacques Yves Gauthier
Petpiboon Prasit
Yves Leblanc
Zhaoyin Wang
Serge Leger
Michel Therien
Original Assignee
Merck Frosst Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/179,467 external-priority patent/US5474995A/en
Application filed by Merck Frosst Canada Inc filed Critical Merck Frosst Canada Inc
Publication of BR9408478A publication Critical patent/BR9408478A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/46—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/48—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups having nitrogen atoms of sulfonamide groups further bound to another hetero atom
    • C07C311/49—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups having nitrogen atoms of sulfonamide groups further bound to another hetero atom to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/24—Sulfones; Sulfoxides having sulfone or sulfoxide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/26—Radicals substituted by sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/58—One oxygen atom, e.g. butenolide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/18—Radicals substituted by singly bound hetero atoms other than halogen by sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Furan Compounds (AREA)
BR9408478A 1994-01-10 1994-12-19 Compound pharmaceutical composition processes of treatment of a disease susceptible to treatment with non-steroidal anti-inflammatory agent and treatment of diseases measured by cyclooxygenase, pharmaceutically effective salt and use of a compound BR9408478A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/179,467 US5474995A (en) 1993-06-24 1994-01-10 Phenyl heterocycles as cox-2 inhibitors
PCT/CA1994/000688 WO1995018799A1 (en) 1994-01-10 1994-12-19 Phenyl heterocycles as cox-2 inhibitors

Publications (1)

Publication Number Publication Date
BR9408478A true BR9408478A (en) 1997-08-26

Family

ID=22656713

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9408478A BR9408478A (en) 1994-01-10 1994-12-19 Compound pharmaceutical composition processes of treatment of a disease susceptible to treatment with non-steroidal anti-inflammatory agent and treatment of diseases measured by cyclooxygenase, pharmaceutically effective salt and use of a compound

Country Status (12)

Country Link
EP (1) EP0739340A1 (en)
JP (1) JP2788677B2 (en)
CN (1) CN1143365A (en)
AU (1) AU1269495A (en)
BG (1) BG63082B1 (en)
BR (1) BR9408478A (en)
CA (1) CA2180651A1 (en)
FI (1) FI108792B (en)
HU (1) HUT74986A (en)
NO (1) NO960393L (en)
SG (1) SG43841A1 (en)
WO (1) WO1995018799A1 (en)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU715676B2 (en) * 1993-03-12 2000-02-10 Merck Frosst Canada & Co. Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases
GB9420616D0 (en) * 1994-10-12 1994-11-30 Merck Sharp & Dohme Method, compositions and use
US5840746A (en) * 1993-06-24 1998-11-24 Merck Frosst Canada, Inc. Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5585504A (en) * 1994-09-16 1996-12-17 Merck & Co., Inc. Process of making cox-2 inhibitors having a lactone bridge
US5968974A (en) 1995-07-19 1999-10-19 Merck & Co., Inc. Method of treating colonic adenomas
KR100454624B1 (en) * 1995-07-19 2004-12-31 머크 앤드 캄파니 인코포레이티드 A pharmaceutical composition for the prevention or treatment of colon adenoma
US6593361B2 (en) 1995-07-19 2003-07-15 Merck & Co Inc Method of treating colonic adenomas
AU775030B2 (en) * 1996-05-17 2004-07-15 Merck Frosst Company Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases
JPH11512754A (en) * 1996-05-17 1999-11-02 メルク エンド カンパニー インコーポレーテッド Composition for once-daily treatment of cyclooxygenase-2-mediated disease
GB9615867D0 (en) * 1996-07-03 1996-09-11 Merck & Co Inc Process of preparing phenyl heterocycles useful as cox-2 inhibitors
US5939069A (en) * 1996-08-23 1999-08-17 University Of Florida Materials and methods for detection and treatment of immune system dysfunctions
DE69825154T2 (en) * 1997-03-14 2005-07-21 Merck Frosst Canada & Co, Kirkland PYRIDAZINONE AS INHIBITORS OF CYCLOOXYGENASE-2
US6004960A (en) * 1997-03-14 1999-12-21 Merck Frosst Canada, Inc. Pyridazinones as inhibitors of cyclooxygenase-2
JP4357004B2 (en) * 1997-04-11 2009-11-04 あすか製薬株式会社 Pyrazole derivative and COX inhibitor containing the same
WO1998051667A1 (en) * 1997-05-16 1998-11-19 Chugai Seiyaku Kabushiki Kaisha Indole derivatives and mono- and diazaindole derivatives
DE69816651T2 (en) 1997-09-05 2004-04-01 Glaxo Group Ltd., Greenford 2,3-DIARYL-PYRAZOLO [1,5-B] PYRIDAZINE DERIVATIVES, THE PRODUCTION AND USE THEREOF AS CYCLOOXYGENASE 2 (COX-2) INHIBITORS
NZ333399A (en) 1997-12-24 2000-05-26 Sankyo Co Cyclooxygenase-2 inhibitors (COX-2) for the prevention and treatment of tumors, cachexia and tumor-metastasis
SA99191255B1 (en) 1998-11-30 2006-11-25 جي دي سيرل اند كو celecoxib compounds
EP1267914B2 (en) 2000-02-04 2013-11-06 Children's Hospital Research Foundation Use of lysosomal acid lipase for treating atherosclerosis and related diseases
US6465509B2 (en) * 2000-06-30 2002-10-15 Merck Frosst Canada & Co. Pyrones as inhibitors of cyclooxygenase-2
DE10133665A1 (en) * 2001-07-11 2003-01-30 Boehringer Ingelheim Pharma Carboxylic acid derivatives, medicaments containing these compounds, their use and preparation
ES2573471T3 (en) 2002-05-09 2016-06-08 The Brigham And Women's Hospital, Inc. 1L1RL-1 as a marker of cardiovascular diseases
CA2489428A1 (en) 2002-06-27 2004-01-08 Nitromed, Inc. Cyclooxygenase-2 selective inhibitors, compositions and methods of use
CA2536622C (en) 2003-08-29 2014-02-11 The Brigham And Women's Hospital, Inc. Inhibitors of cellular necrosis
KR20050051729A (en) * 2003-11-28 2005-06-02 일양약품주식회사 Process for preparing phenyl heterocycles as a cyclooxygenase-2 inhibitor
DE102004027912A1 (en) * 2004-06-09 2005-12-29 Grünenthal GmbH Substituted cyclopentene compounds
ES2439229T3 (en) 2004-10-06 2014-01-22 The Brigham And Women's Hospital, Inc. Relevance of achieved levels of systemic inflammation markers after treatment
US7521435B2 (en) 2005-02-18 2009-04-21 Pharma Diagnostics, N.V. Silicon containing compounds having selective COX-2 inhibitory activity and methods of making and using the same
AU2005332300B2 (en) 2005-05-31 2011-07-07 Mylan Laboratories, Inc. Compositions comprising nebivolol
US8119358B2 (en) 2005-10-11 2012-02-21 Tethys Bioscience, Inc. Diabetes-related biomarkers and methods of use thereof
WO2007109056A2 (en) 2006-03-15 2007-09-27 The Brigham And Women's Hospital, Inc. Use of gelsolin to diagnose and treat inflammatory diseases
EP2924440A3 (en) 2006-06-07 2016-03-09 Health Diagnostic Laboratory, Inc. Markers associated with arteriovascular events and methods of use thereof
BRPI0810409A2 (en) 2007-04-18 2015-02-18 Thethys Bioscience Inc DIABETES-RELATED BIOMARKERS AND METHODS OF USE
GB2460915B (en) 2008-06-16 2011-05-25 Biovascular Inc Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor
TW201201764A (en) 2010-02-01 2012-01-16 Hospital For Sick Children Remote ischemic conditioning for treatment and prevention of restenosis
KR20190000368A (en) 2010-03-31 2019-01-02 더 호스피탈 포 식 칠드런 Use of remote ischemic conditioning to improve outcome after myocardial infarction
AU2013259294B2 (en) 2012-05-11 2017-04-06 Synchronicity Pharma, Inc. Carbazole-containing sulfonamides as cryptochrome modulators
WO2014145022A1 (en) 2013-03-15 2014-09-18 President And Fellows Of Harvard College Hybrid necroptosis inhibitors
TWI690521B (en) 2014-04-07 2020-04-11 美商同步製藥公司 Carbazole-containing amides, carbamates, and ureas as cryptochrome modulators
JP7526168B2 (en) 2018-09-19 2024-07-31 モデルナティエックス インコーポレイテッド PEG lipids and their uses
US12383508B2 (en) 2018-09-19 2025-08-12 Modernatx, Inc. High-purity peg lipids and uses thereof
MX2021005967A (en) 2018-11-21 2021-10-13 Tremeau Pharmaceuticals Inc Purified forms of rofecoxib, methods of manufacture and use.
US10945992B1 (en) 2019-11-13 2021-03-16 Tremeau Pharmaceuticals, Inc. Dosage forms of rofecoxib and related methods
US11161833B1 (en) 2021-04-09 2021-11-02 Tremeau Pharmaceuticals, Inc. Deuterated etoricoxib, methods of manufacture, and use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0388909A3 (en) * 1989-03-22 1991-05-08 Fujisawa Pharmaceutical Co., Ltd. Thiazole compounds, processes for the preparation thereof and pharmaceutical composition comprising the same
CA2078771A1 (en) 1990-04-17 1991-10-18 Gary C. M. Lee 2(5h)-furanones substituted in the 5 and or in the 4 position, as anti-inflammatory agents
GB9012936D0 (en) 1990-06-11 1990-08-01 Fujisawa Pharmaceutical Co Thiophene derivatives,processes for preparation thereof and pharmaceutical composition comprising the same
WO1994015932A1 (en) * 1993-01-15 1994-07-21 G.D. Searle & Co. Novel 3,4-diaryl thiophenes and analogs thereof having use as antiinflammatory agents
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
SK20396A3 (en) * 1993-08-19 1997-03-05 Warner Lambert Co Substituted 2(5h)furanone, 2(5h)thiophenone or 2(5h)pyrrolone derivatives and pharmaceutical compositions on their base

Also Published As

Publication number Publication date
WO1995018799A1 (en) 1995-07-13
SG43841A1 (en) 1997-11-14
NO960393L (en) 1996-07-09
AU1269495A (en) 1995-08-01
NO960393D0 (en) 1996-01-30
JPH09506631A (en) 1997-06-30
FI962800L (en) 1996-09-06
CA2180651A1 (en) 1995-07-13
BG100350A (en) 1996-12-31
FI962800A0 (en) 1996-07-09
HU9601875D0 (en) 1996-09-30
JP2788677B2 (en) 1998-08-20
HUT74986A (en) 1997-03-28
EP0739340A1 (en) 1996-10-30
CN1143365A (en) 1997-02-19
BG63082B1 (en) 2001-03-30
FI108792B (en) 2002-03-28

Similar Documents

Publication Publication Date Title
BR9408478A (en) Compound pharmaceutical composition processes of treatment of a disease susceptible to treatment with non-steroidal anti-inflammatory agent and treatment of diseases measured by cyclooxygenase, pharmaceutically effective salt and use of a compound
RU94041223A (en) Agent for motoneuron disease treatment
BR9406979A (en) Compound, pharmaceutical composition for treating an inflammatory disease susceptible to treatment with a non-steroidal anti-inflammatory agent processes for treating an inflammatory disease and for preparing a pharmaceutically acceptable salt compound use of a non-steroidal anti-inflammatory pharmaceutical composition compound
BR9507656A (en) Compound use of a compound Pharmaceutical composition and processes for the treatment of a patient suffering from pain and for the preparation of a compound
BR9509853A (en) Pharmaceutical formulation use of it and processes to manufacture it to treat a patient in need of anti-thrombotic treatment to treat thromboembolism and to intensify the absorption of the therapeutically active compound
BR9611015A (en) Compound, pharmaceutical composition and process for the treatment of an inflammatory disease susceptible to treatment with a non-toxic non-steroidal anti-inflammatory agent, pharmaceutically acceptable salt, use of a compound
CA2031880A1 (en) Combined anti-inflammatory agent
ATE64297T1 (en) SPRAYABLE PHARMACEUTICAL PREPARATION FOR TOPICAL USE.
BR1100860A (en) Compound, anti-inflammatory drug, pharmaceutical composition, epimer r and epimer s of the compound
FI972642L (en) Galenic unit composition for topical use for contraception and/or for combating sexually transmitted diseases and/or HIV
BR9709097A (en) Pharmaceutical composition for the treatment of diseases mediated by cyclooxygenase process to treat an inflammatory disease susceptible to treatment with an anti-inflammatory agent in the steroid use and oral form of unit dose
BR9711311A (en) Compound pharmaceutical composition use of a compound and processes for the preparation of compounds and for the treatment of a mammal including man
BR9708607A (en) Compound pharmaceutical composition use of a compound process for treating or reducing the risk of inflammatory disease in a patient and for the preparation of a compound and chemical intermediate
FI954007A0 (en) Use of substituted 4-phenyl-6-amino-nicotinic acid derivatives as a medicament
DK349889A (en) USE OF POLYACRYLATES FOR THE PREPARATION OF A MEDICINE
BR9607346A (en) Compound use of a compound, pharmaceutical composition and process for the treatment of a mammal and for and preparation of compounds
PT920865E (en) USE OF "NORASTEMIZOLE" FOR THE TREATMENT OF ALLERGIC DISTURBLES
BR9611555A (en) Compounds pharmaceutical formulation use of a compound process to treat a reversible obstructive airway disease and to prepare the compound
KR940018087A (en) 6-chloro-5-fluoro-3- (2-tenoyl) -2-oxindol-I-carboxamide as analgesic and anti-inflammatory agent
IT8009551A0 (en) E-5-(2-HALOGENOVINIL-)-2'DEOXYCYTIDINES, THEIR METHOD OF PREPARATION AND THEIR USE FOR THE TREATMENT OF VIRUS DISEASES
DK200201483A (en) Dermatological application and dermatological preparation
FI930860A7 (en) Tropolone derivatives and pharmaceutical compositions thereof for the prevention and treatment of ischemic diseases
NO975127D0 (en) Use of non-steroidal anti-inflammatory agents to improve the physiological compatibility of particulate pharmaceutical preparations
BR9509432A (en) Compound of formula (i) its preparation process its use pharmaceutical composition and process for the treatment and / or prophylaxis of arrhythmia and ischemic rhythmic diseases in a human and non-human mammal
FI925544A7 (en) Benzoic acid derivatives for the treatment of leukotriene-related diseases

Legal Events

Date Code Title Description
FB36 Technical and formal requirements: requirement - article 36 of industrial property law
FC Decision: refusal